Dai Ogata1, Keita Tsutsui2,3, Kenjiro Namikawa2, Konosuke Moritani4, Kenta Nakama2, Shunichi Jinnai2, Akira Takahashi2, Shunsuke Tsukamoto4, Yukihide Kanemitsu4, Naoya Yamazaki2. 1. Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan. dogata@ncc.go.jp. 2. Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan. 3. Department of Dermatology, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. 4. Department of Colorectal Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 1040045, Japan.
Abstract
PURPOSE: Primary anorectal melanoma (ARM) accounts for approximately 1.2% of all melanomas and 16.5% of all mucosal melanomas. ARM is associated with the shortest interval to disease progression and the highest rate of metastasis; however, optimal therapeutic strategies for ARM remain controversial. This study aimed to assess the ideal surgical intervention for ARM and to determine the effect of immune checkpoint inhibitors (ICI). METHODS: We included 47 patients with ARM treated at the National Cancer Center Hospital in Japan from 2011 to 2020. We performed a survival analysis for each of these groups: (i) patients with ARM (n = 47); (ii) operable non-stage IV cases at initial presentation (n = 35); and (iii) stage IV cases (n = 32). RESULTS: The 5-year overall survival (OS) was 53.6%, and the median OS was 78.7 months in patients with ARM. No statistically significant difference in 5-year OS was found between rectal and anal sites (50.9% vs. 56.7%). In the non-stage IV subgroup, the type of surgery (abdominoperineal resection or wide local excision) did not correlate with OS (HR 1.85; 95% CI 0.46-7.5; p = 0.39). In the stage IV subgroup, the 2-year OS of the ICI treatment group was 61.4%, whereas that of the dacarbazine regimen group was 0% (p = 0.048). CONCLUSION: Our ARM prognosis was better than that of previous studies. Our findings suggest that the availability of ICI therapy may improve survival in patients with advanced ARM. However, further research is warranted to identify both the clinical and molecular predictors of response to improve patient selection.
PURPOSE: Primary anorectal melanoma (ARM) accounts for approximately 1.2% of all melanomas and 16.5% of all mucosal melanomas. ARM is associated with the shortest interval to disease progression and the highest rate of metastasis; however, optimal therapeutic strategies for ARM remain controversial. This study aimed to assess the ideal surgical intervention for ARM and to determine the effect of immune checkpoint inhibitors (ICI). METHODS: We included 47 patients with ARM treated at the National Cancer Center Hospital in Japan from 2011 to 2020. We performed a survival analysis for each of these groups: (i) patients with ARM (n = 47); (ii) operable non-stage IV cases at initial presentation (n = 35); and (iii) stage IV cases (n = 32). RESULTS: The 5-year overall survival (OS) was 53.6%, and the median OS was 78.7 months in patients with ARM. No statistically significant difference in 5-year OS was found between rectal and anal sites (50.9% vs. 56.7%). In the non-stage IV subgroup, the type of surgery (abdominoperineal resection or wide local excision) did not correlate with OS (HR 1.85; 95% CI 0.46-7.5; p = 0.39). In the stage IV subgroup, the 2-year OS of the ICI treatment group was 61.4%, whereas that of the dacarbazine regimen group was 0% (p = 0.048). CONCLUSION: Our ARM prognosis was better than that of previous studies. Our findings suggest that the availability of ICI therapy may improve survival in patients with advanced ARM. However, further research is warranted to identify both the clinical and molecular predictors of response to improve patient selection.
Authors: Tristan J Dodds; James S Wilmott; Louise A Jackett; Serigne N Lo; Georgina V Long; John F Thompson; Richard A Scolyer Journal: Pathology Date: 2018-11-26 Impact factor: 5.306
Authors: Markus V Heppt; Alexander Roesch; Benjamin Weide; Ralf Gutzmer; Friedegund Meier; Carmen Loquai; Katharina C Kähler; Anja Gesierich; Markus Meissner; Dagmar von Bubnoff; Daniela Göppner; Max Schlaak; Claudia Pföhler; Jochen Utikal; Lucie Heinzerling; Ioana Cosgarea; Jutta Engel; Renate Eckel; Alexander Martens; Laura Mirlach; Imke Satzger; Gabriele Schubert-Fritschle; Julia K Tietze; Carola Berking Journal: Eur J Cancer Date: 2017-06-07 Impact factor: 9.162
Authors: Adrienne Callahan; William F Anderson; Sital Patel; Jill S Barnholtz-Sloan; Jeremy S Bordeaux; Margaret A Tucker; Meg R Gerstenblith Journal: Dermatol Surg Date: 2016-01 Impact factor: 3.398
Authors: Danielle M Bello; Elizabeth Smyth; Daniel Perez; Shaheer Khan; Larissa K Temple; Charlotte E Ariyan; Martin R Weiser; Richard D Carvajal Journal: Dis Colon Rectum Date: 2013-02 Impact factor: 4.585
Authors: Mohammad Adileh; Jonathan B Yuval; Shan Huang; Alexander N Shoushtari; Felipe Quezada-Diaz; Emmanouil P Pappou; Martin R Weiser; Julio Garcia-Aguilar; J Joshua Smith; Philip B Paty; Garrett M Nash Journal: Dis Colon Rectum Date: 2021-05 Impact factor: 4.585